Radiologix reports mixed results for 2Q
Imaging services provider Radiologix reported a net loss of $2.1 million, or 10¢ per diluted share, compared with net income of $276,000, or 2¢ per diluted share for the same period last year. Income from continuing operations excluding charges and a
Imaging services provider Radiologix reported a net loss of $2.1 million, or 10¢ per diluted share, compared with net income of $276,000, or 2¢ per diluted share for the same period last year. Income from continuing operations excluding charges and a gain on sale of operations rose, however, to $1 million, or 5¢ per diluted share, compared with $898,000, or 4¢ per diluted share in 2Q 2003. Earnings before interest, taxes, depreciation, and amortization (EBITDA) were $12.5 million for 2Q 2004, compared with $12.6 million for 2Q 2003. Adjusted EBITDA as a percentage of service fee revenue was 18.4% for the 2Q 2004, compared with 20.3% for 2Q 2003.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
